News ArchivesRead News
Michael J. Fox Foundation: New treatment for Parkinson's Disease
Tuesday April 24, 2012
Digital Journal - The Michael J. Fox Foundation, which was set up in the name of the actor to study Parkinson's Disease, has announced that it is to work with the ‘big pharma’ company Sanofi to look at a potential new treatment for the disease.
The Michael J. Fox Foundation and the company Sanofi have announced trials for a new treatment for Parkinson's Disease.
Parkinson’s Disease is a disorder of the brain that leads to shaking (tremors) and difficulty with walking, movement, and coordination. The Michael J. Fox Foundation (MJFF) is a charitable organization is dedicated to finding a cure for Parkinson’s disease and the development of improved therapies for those living with Parkinson’s. The organization works with the actor, Michael J. Fox, who has Parkinson’s Disease. Fox first developed the disease in 1990.
The drug company Sanofi has entered into a collaboration the MJFF to conduct a clinical trial to assess the safety and tolerability of new drug, a type of inhibitor called phosphodiesterase (coded AVE8112), which is designed to help patients with Parkinson's Disease.
According to the Top News Net, Todd Sherer, Ph.D., Chief Executive Officer of MJFF, said that the drug had:
"Shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson's disease, an area of unmet need where a new treatment could make a tangible difference in patients' lives. Groundbreaking collaborations with like-minded partners such as Sanofi are a hallmark of the Fox Foundation's approach and help us speed scientific advances with potential to improve the treatment of Parkinson's for patients today and in the future."
Under the terms of the collaboration, MJFF will sponsor a phase I b clinical trial to assess the safety and tolerability of AVE8112 in patients with Parkinson's disease. All data and results generated by the clinical trial will be owned by MJFF and shared with Sanofi.
To add to this, the Euro Pharma Review quotes Dr. Elias Zerhouni, President, Global R&D, Sanofi, as saying “The Michael J. Fox Foundation has been a driving force in discovering and developing improved therapies for those living with Parkinson's disease. Through this research collaboration, together we will be able to study Sanofi's pharmaceutical compound for a possible new treatment for PD patients around the world.”
Further development plans will be based upon the results of the study.
Recent NewsJun 13 - Brain Cell Transplants Are Being Tested Once Again For Parkinson's
Jun 12 - Smell Test May Sniff Out Oncoming Parkinson's and Alzheimer's
Jun 8 - Smartphones Track Motor Function in Parkinson's Disease
Jun 8 - GKC Enrolls First Patient in Personal KinetiGraph Trial as Part of NPF’s Parkinson’s Outcomes Project
Jun 8 - Low-fat dairy intake may raise Parkinson's risk
Jun 6 - Patient Voices: Parkinson's Disease
Jun 1 - World-First Trials Have Been Launched to Treat Parkinson's And Blindness With Embryonic Stem Cells
May 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression
Apr 21 - TOLEDO Trial: Apomorphine Infusions Reduce 'Off' Time in Parkinson's Disease
Apr 21 - New drug provides long-awaited breakthrough for Parkinson's psychosis